This article is more than 5 years old. Information may no longer be current.

Orexigen obtains patent for treatment of insulin resistance

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

With existing patents for NB32 in the weight loss arena, the manufacturer announced its newest patent in the role of treating insulin resistance.

“As we ready NB32 for commercialization and plan for lifecycle development, the issuance of this patent adds to our growing intellectual property portfolio and, we believe, enhances the value of the asset,” Michael Narachi, CEO of Orexigen, said in a press release.

Like the existing patents, which Orexigen refers to as the Weber/Cowley patents, this patent for treating insulin resistance will expire in 2024. The company holds similar patents in Europe and has submitted one for insulin resistance as well.

In previous studies, the drug has shown favorable outcomes in weight loss and glycemic control and is forecasted to receive FDA approval on September 11.

Earlier this summer, the European regulating body issued its List of Outstanding Issues, delaying final approval.

For more information:

Naltrexone/bupropion interim data yield favorable CV outcomes

Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent